Arch Biopartners Inc. (ACHFF)
USD 1.24
(0.81%)
USD 1.24
(0.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.35 Million CAD | -277.44% |
| 2022 | -1.38 Million CAD | -19.27% |
| 2021 | -1.16 Million CAD | 74.86% |
| 2020 | -4.63 Million CAD | -96.19% |
| 2019 | -2.36 Million CAD | 26.92% |
| 2018 | -3.23 Million CAD | -69.96% |
| 2017 | -1.9 Million CAD | -90.05% |
| 2016 | -1 Million CAD | -10.34% |
| 2015 | -906.89 Thousand CAD | -143.12% |
| 2014 | -373.02 Thousand CAD | -95.07% |
| 2013 | -191.22 Thousand CAD | 41.94% |
| 2012 | -329.38 Thousand CAD | 25.6% |
| 2011 | -442.68 Thousand CAD | -213.9% |
| 2010 | -141.02 Thousand CAD | 22.42% |
| 2009 | -181.79 Thousand CAD | 65.25% |
| 2008 | -523.18 Thousand CAD | -124.24% |
| 2007 | -233.31 Thousand CAD | -458.13% |
| 2006 | 65.14 Thousand CAD | 118.52% |
| 2005 | -351.75 Thousand CAD | 66.94% |
| 2004 | -1.06 Million CAD | -94.37% |
| 2003 | -547.37 Thousand CAD | -146.15% |
| 2002 | -222.37 Thousand CAD | -13.75% |
| 2001 | -195.49 Thousand CAD | 80.51% |
| 2000 | -1 Million CAD | -35.78% |
| 1999 | -738.66 Thousand CAD | -43.84% |
| 1998 | -513.53 Thousand CAD | 56.43% |
| 1997 | -1.17 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1 Million CAD | -349.57% |
| 2024 Q2 | -1.14 Million CAD | -14.24% |
| 2024 Q3 | -862.93 Thousand CAD | 24.57% |
| 2023 Q2 | -968.23 Thousand CAD | 56.2% |
| 2023 Q3 | -577.42 Thousand CAD | 40.36% |
| 2023 Q4 | 401.25 Thousand CAD | 169.49% |
| 2023 FY | -5.24 Million CAD | -277.44% |
| 2023 Q1 | -2.21 Million CAD | -384.93% |
| 2022 Q4 | -455.89 Thousand CAD | -72.28% |
| 2022 Q3 | -264.62 Thousand CAD | 45.94% |
| 2022 Q2 | -489.46 Thousand CAD | -172.85% |
| 2022 Q1 | -179.38 Thousand CAD | -126.93% |
| 2022 FY | -1.38 Million CAD | -19.27% |
| 2021 Q1 | -1.65 Million CAD | -2.6% |
| 2021 Q4 | 666.23 Thousand CAD | -24.05% |
| 2021 FY | -1.16 Million CAD | 74.86% |
| 2021 Q3 | 877.24 Thousand CAD | 183.07% |
| 2021 Q2 | -1.05 Million CAD | 36.1% |
| 2020 Q1 | -732.6 Thousand CAD | 24.39% |
| 2020 Q2 | -97.1 Thousand CAD | 86.75% |
| 2020 Q3 | -2.22 Million CAD | -2189.67% |
| 2020 Q4 | -1.61 Million CAD | 27.56% |
| 2020 FY | -4.63 Million CAD | -96.19% |
| 2019 Q1 | -834.02 Thousand CAD | -7.47% |
| 2019 FY | -2.36 Million CAD | 26.92% |
| 2019 Q4 | -968.93 Thousand CAD | -1112.13% |
| 2019 Q2 | -508.66 Thousand CAD | 39.01% |
| 2019 Q3 | -79.93 Thousand CAD | 84.29% |
| 2018 Q2 | -615.3 Thousand CAD | -80.52% |
| 2018 Q3 | -1.49 Million CAD | -143.77% |
| 2018 Q1 | -340.84 Thousand CAD | -55.22% |
| 2018 FY | -3.23 Million CAD | -69.96% |
| 2018 Q4 | -776.05 Thousand CAD | 48.26% |
| 2017 Q1 | -235.36 Thousand CAD | 31.61% |
| 2017 Q2 | -153.13 Thousand CAD | 34.94% |
| 2017 Q4 | -219.58 Thousand CAD | 83.18% |
| 2017 FY | -1.9 Million CAD | -90.05% |
| 2017 Q3 | -1.3 Million CAD | -752.52% |
| 2016 FY | -1 Million CAD | -10.34% |
| 2016 Q2 | -308.19 Thousand CAD | -85.79% |
| 2016 Q3 | -182.42 Thousand CAD | 40.81% |
| 2016 Q4 | -344.14 Thousand CAD | -88.65% |
| 2016 Q1 | -165.88 Thousand CAD | 13.01% |
| 2015 FY | -906.89 Thousand CAD | -143.12% |
| 2015 Q1 | -365.87 Thousand CAD | -253.19% |
| 2015 Q4 | -190.69 Thousand CAD | -20.63% |
| 2015 Q3 | -158.08 Thousand CAD | 17.77% |
| 2015 Q2 | -192.24 Thousand CAD | 47.46% |
| 2014 Q1 | -52.76 Thousand CAD | 13.07% |
| 2014 FY | -373.02 Thousand CAD | -95.07% |
| 2014 Q2 | -91.81 Thousand CAD | -74.01% |
| 2014 Q4 | -103.59 Thousand CAD | 17.03% |
| 2014 Q3 | -124.85 Thousand CAD | -35.99% |
| 2013 Q1 | -32.52 Thousand CAD | 65.48% |
| 2013 FY | -191.22 Thousand CAD | 41.94% |
| 2013 Q4 | -60.69 Thousand CAD | -237.8% |
| 2013 Q2 | -80.04 Thousand CAD | -146.1% |
| 2013 Q3 | -17.96 Thousand CAD | 77.55% |
| 2012 Q4 | -94.21 Thousand CAD | -6.01% |
| 2012 Q3 | -88.87 Thousand CAD | -48.19% |
| 2012 FY | -329.38 Thousand CAD | 25.6% |
| 2012 Q1 | -87.22 Thousand CAD | 2.78% |
| 2012 Q2 | -59.97 Thousand CAD | 31.25% |
| 2011 Q1 | -108.32 Thousand CAD | -33.86% |
| 2011 Q3 | -163.6 Thousand CAD | -101.88% |
| 2011 FY | -442.68 Thousand CAD | -213.9% |
| 2011 Q4 | -89.72 Thousand CAD | 45.16% |
| 2011 Q2 | -81.03 Thousand CAD | 25.19% |
| 2010 Q4 | -80.92 Thousand CAD | -169.45% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2010 Q3 | -30.03 Thousand CAD | -24.94% |
| 2010 FY | -141.02 Thousand CAD | 22.42% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2009 Q1 | -429.82 Thousand CAD | -585.11% |
| 2009 Q2 | -57.5 Thousand CAD | 86.62% |
| 2009 Q3 | -35.66 Thousand CAD | 37.98% |
| 2009 FY | -181.79 Thousand CAD | 65.25% |
| 2009 Q4 | -26.76 Thousand CAD | 24.96% |
| 2008 Q3 | -71.85 Thousand CAD | 34.74% |
| 2008 Q1 | -177.17 Thousand CAD | -1504.39% |
| 2008 FY | -523.18 Thousand CAD | -124.24% |
| 2008 Q4 | 88.6 Thousand CAD | 223.31% |
| 2008 Q2 | -110.1 Thousand CAD | 37.85% |
| 2007 FY | -233.31 Thousand CAD | -458.13% |
| 2007 Q3 | -4566.00 CAD | 88.74% |
| 2007 Q4 | -11.04 Thousand CAD | -141.85% |
| 2007 Q2 | -40.53 Thousand CAD | -116.62% |
| 2007 Q1 | 243.84 Thousand CAD | 593.22% |
| 2006 Q1 | -224.92 Thousand CAD | -243.16% |
| 2006 Q2 | -94.99 Thousand CAD | 57.77% |
| 2006 Q3 | -23.29 Thousand CAD | 75.47% |
| 2006 Q4 | -49.43 Thousand CAD | -112.2% |
| 2006 FY | 65.14 Thousand CAD | 118.52% |
| 2005 FY | -351.75 Thousand CAD | 66.94% |
| 2005 Q4 | 157.11 Thousand CAD | 234.42% |
| 2005 Q3 | -116.88 Thousand CAD | 30.03% |
| 2005 Q2 | -167.06 Thousand CAD | 74.69% |
| 2005 Q1 | -660.14 Thousand CAD | -91.87% |
| 2004 Q1 | -358.58 Thousand CAD | -267.67% |
| 2004 Q4 | -344.05 Thousand CAD | -856.17% |
| 2004 Q3 | 45.5 Thousand CAD | 144.15% |
| 2004 FY | -1.06 Million CAD | -94.37% |
| 2004 Q2 | -103.05 Thousand CAD | 71.26% |
| 2003 Q1 | -50.89 Thousand CAD | -195.45% |
| 2003 FY | -547.37 Thousand CAD | -146.15% |
| 2003 Q3 | -15.59 Thousand CAD | 79.39% |
| 2003 Q2 | -75.66 Thousand CAD | -48.66% |
| 2003 Q4 | -97.53 Thousand CAD | -525.4% |
| 2002 Q1 | -8874.00 CAD | 90.12% |
| 2002 FY | -222.37 Thousand CAD | -13.75% |
| 2002 Q3 | -82.08 Thousand CAD | -19.81% |
| 2002 Q4 | -17.22 Thousand CAD | 79.01% |
| 2002 Q2 | -68.5 Thousand CAD | -672.02% |
| 2001 FY | -195.49 Thousand CAD | 80.51% |
| 2001 Q3 | -55.9 Thousand CAD | -36.19% |
| 2001 Q2 | -41.04 Thousand CAD | 89.98% |
| 2001 Q1 | -409.6 Thousand CAD | -75.48% |
| 2001 Q4 | -89.85 Thousand CAD | -60.73% |
| 2000 FY | -1 Million CAD | -35.78% |
| 2000 Q3 | -300.81 Thousand CAD | -408.9% |
| 2000 Q4 | -233.42 Thousand CAD | 22.4% |
| 2000 Q2 | -59.11 Thousand CAD | 87.08% |
| 2000 Q1 | -457.43 Thousand CAD | -446.01% |
| 1999 Q2 | -69.15 Thousand CAD | 74.84% |
| 1999 Q1 | -274.85 Thousand CAD | -396.22% |
| 1999 FY | -738.66 Thousand CAD | -43.84% |
| 1999 Q3 | -128.29 Thousand CAD | -85.5% |
| 1999 Q4 | -83.77 Thousand CAD | 34.7% |
| 1998 Q2 | -127.9 Thousand CAD | 0.0% |
| 1998 Q4 | -55.38 Thousand CAD | 56.69% |
| 1998 FY | -513.53 Thousand CAD | 56.43% |
| 1998 Q3 | -127.9 Thousand CAD | 0.0% |
| 1997 FY | -1.17 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | 81.2% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 33.489% |
| CSL Limited | 3.7 Billion USD | 100.091% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.099% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -388.414% |
| BioStem Technologies, Inc. | -7.77 Million USD | 56.869% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -167.13% |
| Qrons Inc. | -643.67 Thousand USD | -421.249% |
| Nascent Biotech, Inc. | -2.22 Million USD | -50.464% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.956% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 49.531% |
| Skye Bioscience, Inc. | -13.67 Million USD | 75.459% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -707.54% |
| Rebus Holdings, Inc. | -664 Thousand USD | -405.295% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 78.858% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -151.242% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.193% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -761.247% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.326% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 168.266% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1181.936% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.575% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -17.704% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -118.428% |
| Mesoblast Limited | -84.14 Million USD | 96.013% |
| Marizyme, Inc. | -34.08 Million USD | 90.157% |
| Genus plc | 6.4 Million USD | 152.424% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 134.439% |
| Pharming Group N.V. | -4.87 Million USD | 31.24% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -68.9% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -260.235% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 59.818% |
| ContraFect Corporation | -56.88 Million USD | 94.102% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 26.337% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -139.314% |
| IMV Inc. | -38.67 Million USD | 91.324% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -21.969% |
| MultiCell Technologies, Inc. | -722.81 USD | -464082.704% |
| ONE Bio Corp. | 13.68 Million USD | 124.523% |
| Accustem Sciences Inc. | -3.74 Million USD | 10.444% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.312% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -594.561% |
| Q BioMed Inc. | -3.44 Million USD | 2.625% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 194.779% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -27.693% |
| Biomind Labs Inc. | -1 Million USD | -232.325% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.897% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -15.645% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -79.962% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11101.786% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -73.608% |
| GB Sciences, Inc. | -1.42 Million USD | -136.194% |
| Alpha Cognition Inc. | -9.7 Million USD | 65.431% |
| HST Global, Inc. | -140.9 Thousand USD | -2281.116% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -198.261% |
| Halberd Corporation | -75.05 Thousand USD | -4370.565% |
| Enzolytics Inc. | -2.14 Million USD | -56.141% |
| Agentix Corp. | -1.37 Million USD | -144.589% |
| Resverlogix Corp. | -12.74 Million USD | 73.683% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -5.899% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.211% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -221.375% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -14.925% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -112.439% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 1.463% |
| AVAX Technologies, Inc. | 6.69 Million USD | 150.13% |
| Zenith Capital Corp. | -8.94 Million USD | 62.483% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -19159.279% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -36.649% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1856.252% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -67.36% |
| Kadimastem Ltd | -3.04 Million USD | -10.358% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -240.953% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1748.725% |
| LadRx Corporation | -3.82 Million USD | 12.252% |
| Cell Source, Inc. | -4.32 Million USD | 22.43% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -388.414% |
| NovAccess Global Inc. | -2.46 Million USD | -36.015% |
| Affymax, Inc. | -15.04 Million USD | 77.701% |
| Itoco Inc. | -919.14 Thousand USD | -265.032% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 20.839% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -199.835% |
| Mobile Lads Corp. | -554.55 Thousand USD | -505.024% |
| CytoDyn Inc. | -18.05 Million USD | 81.42% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13229.992% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1424.532% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -494.125% |
| SYBLEU INC | -149.18 Thousand USD | -2149.068% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -84.723% |
| International Stem Cell Corporation | -663 Thousand USD | -406.057% |
| Bioxytran, Inc. | -3.82 Million USD | 12.172% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6273.782% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -16395.374% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 90.748% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -107.365% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -355.966% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -7.848% |
| Neutra Corp. | -229.48 Thousand USD | -1362.032% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 80.87% |
| PureTech Health plc | -146.19 Million USD | 97.705% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 84.388% |
| IXICO plc | -1.43 Million USD | -133.484% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 64.649% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.245% |
| CSL Limited | 3.81 Billion USD | 100.088% |
| Cellectis S.A. | -108.85 Million USD | 96.918% |